Cited by 694COVID-19 Clinical Research StudiesBlood Coagulation and Thrombosis MechanismsVenous Thromboembolism Diagnosis and Management

The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management

Open access
Abou-Ismail, Mouhamed Yazan, Diamond, Akiva, Kapoor, Sargam, Arafah, Yasmin, Nayak, Lalitha·2020·Thrombosis Research

Abstract

The 2019 coronavirus disease (COVID-19) presents with a large variety of clinical manifestations ranging from asymptomatic carrier state to severe respiratory distress, multiple organ dysfunction and death. While it was initially considered primarily a respiratory illness, rapidly accumulating data suggests that COVID-19 results in a unique, profoundly prothrombotic milieu leading to both arterial and venous thrombosis. Consistently, elevated D-dimer level has emerged as an independent risk factor for poor outcomes, including death. Several other laboratory markers and blood counts have also been associated with poor prognosis, possibly due to their connection to thrombosis. At present, the pathophysiology underlying the hypercoagulable state is poorly understood. However, a growing body of data suggests that the initial events occur in the lung. A severe inflammatory response, originating in the alveoli, triggers a dysfunctional cascade of inflammatory thrombosis in the pulmonary vasculature, leading to a state of local coagulopathy. This is followed, in patients with more severe disease, by a generalized hypercoagulable state that results in macro- and microvascular thrombosis. Of concern, is the observation that anticoagulation may be inadequate in many circumstances, highlighting the need for alternative or additional therapies. Numerous ongoing studies investigating the pathophysiology of the COVID-19 associated coagulopathy may provide mechanistic insights that can direct appropriate interventional strategies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.thromres.2020.06.029

Cites

140 of 140 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [19]Guan W.J. Clinical characteristics of coronavirus disease 2019 in China N. Engl. J. Med. 382 18 2020 1708 1720 32109013 PMC7092819
  2. [24]Klok F.A. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Thromb. Res. 191 2020 145 147 32291094 PMC7146714
  3. [111]Lodigiani C. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy Thromb Res. 2020 9 14 PMC7177070 32353746

Cited by

Sorted by citations

Authors
Abou-Ismail, M. Y., Diamond, A., Kapoor, S., Arafah, Y., & Nayak, L.
Affiliations
  • University Hospitals of Cleveland (US)
  • Alaska Native Medical Center (US)
Corresponding author
Nayak, Lalitha
Venue
Thrombosis Research
Publisher
Elsevier BV
Published
2020-10
Volume
194
Pages
101-115
ISSN
0049-3848 (ISSN-L)
OpenAlex
W3036625914
Cited by
694
References
140
Citations by year
2026: 14 · 2025: 50 · 2024: 88 · 2023: 109 · 2022: 183 · 2021: 196 · 2020: 54
FWCI
6.41
Type
journal article
Language
en
Update notices
erratum (2021-08-01)
Open access
Locations
  • Thrombosis Research (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Scholarly Commons @ Case Western Reserve University (submittedVersion)
Funders
National Heart, Lung, and Blood Institute (HL142647-01, HL121131-01, U01 HL143402.)
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords
COVID-19 pandemic, hypercoagulability, coagulopathy, thrombosis, D-dimer, arterial thrombosis, venous thrombosis, pulmonary thrombosis, anticoagulation, prognostic factors, pathophysiology
MeSH terms
COVID-19, COVID-19 Drug Treatment, Animals, Anti-Inflammatory Agents, Anticoagulants, Blood Coagulation, Humans, Inflammation, Thrombosis, Incidence, Thrombophilia, Venous Thromboembolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review